Efaluzimab in the treatment of psoriasis.
We present a review of the literature concerning treatment of psoriasis with humanized monoclonal antibody (hu 1124, efaluzimab, Xanelin) against the CD11a component of lymphocyte-function-associated antigen-1 (LFA-1). Efaluzimab inhibits the interaction of CD11a (LFA-1) with various ICAM molecules. Because ICAM-1 (CD54) is expressed on activated endothelial cells and antigen presenting cells (APCs), the antibody inhibits both the APC-T cell interaction and the T- cell adhesion to endothelial cells, their subsequent activation, which results in decreasing of transendothelial migration. Treatment with Efaluzimab was well tolerated and the majority adverse events were dose-related. Adverse events were described as mild at doses of 0.3 mg/kg or less and included mild chills, abdominal discomfort, headache, and fever (flu-like complaints), apart from this white blood cell counts and lymphocyte counts transient increase were observed. Headache was the most common dose-limiting toxicity observed at a single dose of 0.6 mg/kg or higher.
Chair and Department of Dermatology, Medical University of Lublin.
Aldona
A
Pietrzak
Monika
M
Podhorecka
Grazyna
G
Chodorowska
Jacek
J
Roliński
Janusz
J
Urban
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018845:CD11 Antigens / Q000187:drug effects; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000187:drug effects; D011565:Psoriasis / Q000188:drug therapy*; D013601:T-Lymphocytes / Q000378:metabolism*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018845:CD11 Antigens; D018799:Intercellular Adhesion Molecule-1; C472181:efalizumab